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Abstract
Background: It has been recognized that dermal fibroblasts and matrix metalloproteases (MMP)
play crucial roles in wound healing process in skin. Thrombin was found to stimulate IL-8 release
from human dermal fibroblasts (HDFs). However, little is known of the effect of thrombin on
secretion of MMPs from dermal fibroblasts. In the present study, the influence of thrombin on
proMMP-2 and proMMP-9 activity release from primary cultured HDFs, and its potential signaling
pathways were investigated.
Results: The results showed that thrombin induced proMMP-9, but not proMMP-2 release from
HDFs in a dose dependent manner at 6 h following incubation. Thrombin also upregulated
expression of proMMP-9 mRNA in HDFs. Hirudin completely abolished the action of thrombin on
HDFs. An agonist peptide of protease-activated receptor-1, SFLLR-NH2 stimulated an enhanced
release of proMMP-9 from HDFs. AG490, an inhibitor of STAT3 inhibited basal and thrombin-
provoked proMMP-9 release and phosphorylation of STAT3. PD98059, an inhibitor of MAPK and
LY294002, an inhibitor PI3K failed to significantly inhibit thrombin induced proMMP-9 release.
Conclusion: Thrombin is a potent stimulus of proMMP-9 release from HDFs. Thrombin induced
proMMP-9 release is most likely through activation of PAR-1. JAK/STAT3 signaling pathway is
involved in proMMP-9 release from HDFs.
Background
The MMPs, also called matrixin, play a key role in the
processes of embryonic development, morphogenesis,
reproduction, tissue remodeling and tumor invasion and
metastasis [1]. MMP-2 and MMP-9 are geletinases, which
degrade type IV collagen, a major constituent of basement
membranes, denatured interstitial collagens (gelatins),
laminin, elastin, and fibronectin [2]. They are secreted as
zymogens with a molecular weight of proMMP-2 being 72
kDa and proMMP-9 being 97 kDa. Dermal fibroblasts
produce and organize the extracellular matrix of the der-
mis. They are able to generate MMPs including MMP-2
and MMP-9, collagen, other extracellular matrix compo-
nents and cytokines upon activation [3].
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In recent years, thrombin has been discovered to play
important roles in inflammatory and tissue repair proc-
esses by influencing vascular and blood cells including
endothelial cells [4], fibroblasts [5], vascular smooth mus-
cle cells [6], T lymphocytes [7], eosinophils [8] and mono-
cytes [9]. As a serine protease, thrombin exerts many of its
actions through proteolytic activation of its receptors
including protease-activated receptor (PAR)-1, PAR-3 and
PAR-4 [10]. These receptors can also be activated without
proteolytic cleavage using five to six residue peptides cor-
responding to the new N termini of the cleaved receptors
[11]. PARs are 'single-use' receptors: proteolytic activation
is irreversible and the cleaved receptors are degraded in
lysosomes. Thus, PARs play important roles in 'emergency
situations', such as trauma and inflammation, although
their other potential downstream signaling targets have
not been fully established [12].
Recently, it was demonstrated that human dermal fibrob-
lasts express PAR-1 and PAR-3, and thrombin is able to
stimulate IL-8 release from these fibroblasts predomi-
nantly through MAPK/ERK and p38 MAPK signaling path-
ways [13]. However, little is known of influence of
thrombin on MMP-9 and MMP-2 release from fibroblasts.
We therefore investigate the action of thrombin on MMP-
9 and MMP-2 release from primary HDFs and its potential
intracellular signaling pathways in the present study.
Results
Expression of PARs in HDFs
Immunofluorescence staining showed that primary cul-
tured HDFs expressed proteins of PAR-1, PAR-2, PAR-3,
but not PAR-4 (Fig. 1). An agarose gel electrophoresis
revealed that primary cultured HDFs expressed PAR-1,
PAR-2, PAR-3, but not PAR-4 mRNAs (Fig. 2).
Influence of thrombin on proMMP-2 and proMMP-9 
secretion from HDFs
Thrombin at the concentrations of 0.1, 1 and 5 U/ml pro-
voked a concentration-dependent increase in proMMP-9
activity from primary cultured HDFs following 6 h incu-
bation. As little as 1 U/ml of thrombin was able to induce
significant increase in release of proMMP-9 activity from
HDFs (Fig. 3A). The upregulated expression of MMP-9
mRNA in HDFs was found when HDFs were incubated
with thrombin at 1 and 5 U/ml for 6 h (Fig. 3C). In con-
trast, thrombin at the concentrations tested had no siginif-
icant effect either on secretion of proMMP-2 activity (Fig.
3A) or on expression MMP-2 mRNA (data not shown) fol-
lowing 6 h incubation period. Hirudin, a specific
thrombin inhibitor at the concentrations of 1 and 5 U/ml
completely abolished thrombin-induced release of
proMMP-9 activity after 6 h incubation (Fig. 3B).
SFLLR-NH2, a PAR-1 agonist peptide at the concentration
of 100 µM induced a significant release of proMMP-9
activity at 6 h following incubation (Fig. 4A). It appeared
that SFLLR-NH2  at 100 µM was able to also elicit
enhanced secretion of proMMP-2 activity from HDFs
though this did not reach statistical significance level (Fig.
4A). As a positive control, TGFβ at 10 ng/ml induced sig-
nificant release of proMMP-9 activity from HDFs (Fig.
4A). RLLFS-NH2, a reverse peptide of SFLLR-NH2 had little
effect on release of proMMP-9 and proMMP-2 activities
Determination of expression of PAR proteins in HDFs by  immunofluorescence staining Figure 1
Determination of expression of PAR proteins in HDFs by 
immunofluorescence staining. HDFs appear to express PAR-
1, PAR-2, PAR-3, but not PAR-4 proteins.BMC Cell Biology 2007, 8:14 http://www.biomedcentral.com/1471-2121/8/14
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from HDFs (Fig. 4B). A PAR-1 blocking antibody com-
pletely blocked SFLLR-NH2 induced release of proMMP-9
activity (Fig. 4B).
Effect of PD98059, LY294002 and AG490 on thrombin-
induced release of proMMP-9 activity
Following 2 h and 6 h incubation periods, AG490, a JAK/
STAT3 pathway inhibitor reduced significantly basal and
thrombin-provoked release of proMMP-9 activity (Fig.
5A) and expression of proMMP-9 mRNA in HDFs (Fig.
5B). It was observed also that PD98059, an inhibitor of
MAPK pathway and LY294002, an inhibitor of PI3K were
able to inhibit thrombin-provoked release of proMMP-9
activity from HDFs though the inhibition does not reach
statistical significance level (Fig. 5A). AG490, PD98059
and LY294002 have little influence on basal or thrombin-
induced release of proMMP-2 activity from HDFs follow-
ing both 2 h and 6 h incubation periods (Fig. 5A).
Effect of AG490 on STAT3 phosphorylation in HDFs
Thrombin at a concentration of 5 U/ml enhanced phos-
phorylation of STAT3 in HDFs following 30 min, 2 h and
6 h incubation periods. The action of thrombin on JAK/
STAT3 pathway was completely abolished by AG490.
AG490 also significantly reduced basal phosphorylation
of STAT3 in HDFs following 30 min, 2 h and 6 h incuba-
tion periods (Fig. 6).
Effect of PD98059 on ERK 1/2 phosphorylation in HDFs
Thrombin at a concentration of 5 U/ml induced an
enhanced phosphorylation of ERK1/2 in HDFs following
2 h and 6 h incubation periods. PD98059 was able to
completely block thrombin induced phosphorylation of
ERK1/2 when it was incubated with HDFs for 2 h and 6 h.
PD98059 inhibited also basal phosphorylation of ERK1/
2 in HDFs following 2 h and 6 h incubation periods (Fig.
7)
Effects of thrombin (Th, U/ml), hirudin (Hir, U/ml) on release  of MMP-2 and MMP-9 activities, and influence of Th on  expression of MMP-9 mRNA in HDFs Figure 3
Effects of thrombin (Th, U/ml), hirudin (Hir, U/ml) on release 
of MMP-2 and MMP-9 activities, and influence of Th on 
expression of MMP-9 mRNA in HDFs. The cells were incu-
bated with Th, Hir at 37°C for 6 h. Gelatin zymography was 
used to detect proMMP-2 and proMMP-9 activities. (A) 
MMP-2 and MMP-9 activities released from HDFs in 
response to various concentrations of Th; (B) MMP-2 and 
MMP-9 activities released from HDFs in response to Th at 5 
U/ml and Hir; (C) MMP-9 mRNA expression in HDFs in 
response to various concentrations of Th. The values shown 
are Mean ± SD for four separate experiments. Cells from 
each one of the four dermal fibroblast donors were used for 
one independent experiment. * P < 0.05 in comparison with 
the response to medium alone (Con); † P < 0.05 in compari-
son with the response to the corresponding stimulus alone.
Determination of expression of PAR mRNAs in HDFs by RT- PCR Figure 2
Determination of expression of PAR mRNAs in HDFs by RT-
PCR. HDFs express PAR-1, PAR-2, PAR-3, but not PAR-4 
mRNAs.BMC Cell Biology 2007, 8:14 http://www.biomedcentral.com/1471-2121/8/14
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Effect of LY294002 on Akt phosphorylation in HDFs
Thrombin at a concentration of 5 U/ml failed to induce
significantly increased phosphorylation of Akt in HDFs.
LY294002 diminished basal phosphorylation of Akt in
HDFs at 2 h, but not 6 h following incubation, but had lit-
tle effect on the action of thrombin in HDFs (Fig. 8).
Discussion
It was found that thrombin was able to induce proMMP-
9 secretion from primary cultured HDFs, indicating that it
is likely involved in the tissue remodeling process in the
body. In the parallel experiment, thrombin failed to stim-
ulate enhanced proMMP-2 activity release from HDFs,
implicating that the action of thrombin on HDFs was a
selective one. Selective release of MMP-9 from fibroblasts
has been observed previously with rat mast cell sonicate
[14], which may support the above view. Since the
proMMP-9 activity released from HDFs in response to
thrombin at 1 and 5 U/ml and SFLLR-NH2 at 100 µM was
similar to the activity released in response to TGFβ at 10
ng/ml, it implicated that thrombin was a potent secre-
togogue of proMMP-9 activity release from HDFs.
It appeared that thrombin induced proMMP-9 release was
most likely through activation of PAR-1 as HDFs express
PAR-1, PAR-2 and PAR-3, PAR-2 is not a receptor for
Effect of AG490 (AG), PD98059 (PD) and LY294002 (LY) on  MMP-2 and MMP-9 activity release and MMP-9 mRNA  expression in HDFs Figure 5
Effect of AG490 (AG), PD98059 (PD) and LY294002 (LY) on 
MMP-2 and MMP-9 activity release and MMP-9 mRNA 
expression in HDFs. (A) HDFs were incubated with AG490 
(40 µM), PD98059 (50 µM) and LY294002 (40 µM) in the 
presence or absence of thrombin (Th, 5 U/ml) at 37°C for 2 
h and 6 h, and MMP-2 and MMP-9 activities were detected 
with zymograph. (B) HDFs were incubated with AG490, 
PD98059 and LY294002 in the presence or absence of Th at 
37°C for 6 h, and MMP-9 mRNA was detected by RT-PCR 
analysis. The relative levels of MMP-9 mRNA were expressed 
as the ratio to β-actin. The values shown are Mean ± SD for 
four separate experiments. Cells from each one of the four 
dermal fibroblast donors were used for one independent 
experiment. † P < 0.05 compared with the response to 
medium alone (Con); * P < 0.05 compared with the response 
to thrombin alone.
Effects of SFLLR-NH2 (SFL, µM) and RLLFS-NH2 (RLL, µM)  on release of MMP-2 and MMP-9 activities in HDFs Figure 4
Effects of SFLLR-NH2 (SFL, µM) and RLLFS-NH2 (RLL, µM) 
on release of MMP-2 and MMP-9 activities in HDFs. The cells 
were incubated with SFL, RLL or PAR-1 blocking antibody 
(BA, µg/ml) at 37°C for 6 h, respectively. Gelatin zymography 
was used to detect proMMP-2 and proMMP-9 activities. (A) 
MMP-2 and MMP-9 activities released from HDFs in 
response to various concentrations of SFL and TGFβ at 10 
ng/ml (as a positive control); (B) MMP-2 and MMP-9 activities 
released from HDFs in response to SFL, RLL and BA. The 
values shown are Mean ± SD for four separate experiments. 
Cells from each one of the four dermal fibroblast donors 
were used for one independent experiment. * P < 0.05 in 
comparison with the response to medium alone (Con); † P < 
0.05 in comparison with the response to the corresponding 
stimulus alone.BMC Cell Biology 2007, 8:14 http://www.biomedcentral.com/1471-2121/8/14
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thrombin and PAR-3 could not be activated by thrombin
alone [15]. Our preliminary experiment revealed that a
specific agonist peptide of PAR-3, TFRGAP-NH2 had little
effect on proMMP-9 or proMMP-2 release from HDFs
(data not shown). The observations that an agonist pep-
tide of PAR-1, SFLLR-NH2, but not its reverse peptide was
able to stimulate proMMP-9 release from HDFs, and that
PAR-1 blocking antibody completely blocked the action
of SFLLR-NH2 on HDFs comfirmed that activation of PAR-
1 was responsible for thrombin induced release of
proMMP-9 from HDFs. The PAR-1 blocking antibody
ATAP2 employed in the present study was reported previ-
ously as a cleavage-blocking anti-PAR-1 antibody, which
abolished completely activated-protein-C induced activa-
tion of PAR-1 [16]. It has been reported before that activa-
tion of PAR-1 could cause release of IL-8 [13], monocyte
chemotactic protein-1 [17] and IL-6 [18] from fibroblasts,
which may further support our current finding that stim-
ulation of proMMP-9 release from HDFs by thrombin is
likely through activation of PAR-1.
Western blot analysis of effect of PD98059 (PD), a MAPK  pathway inhibitor on the phosphorylation of ERK1/2 in HDFs Figure 7
Western blot analysis of effect of PD98059 (PD), a MAPK 
pathway inhibitor on the phosphorylation of ERK1/2 in 
HDFs. Cells were incubated with PD (50 µM), thrombin (Th, 
5 U/ml) or Th + PD at 37°C for 2 h or 6 h, respectively. 
Densitometry analysis of immunoblots was carried out using 
a Scion Image software. The relative levels of phospho-ERK1/
2 were expressed as the ratio to β-actin. The values shown 
are Mean ± SD for four separate experiments. Cells from 
each one of the four dermal fibroblast donors were used for 
one independent experiment. † P < 0.05 compared with the 
response to medium alone (Con); * P < 0.05 compared with 
the response to thrombin alone.
Western blot analysis of effect of AG490 (AG), a JAK/STAT  pathway inhibitor on the phosphosrylation of STAT3 in  HDFs Figure 6
Western blot analysis of effect of AG490 (AG), a JAK/STAT 
pathway inhibitor on the phosphosrylation of STAT3 in 
HDFs. Cells were incubated with AG (40 µM), thrombin (Th, 
5 U/ml) or Th + AG at 37°C for 30 min, 2 h and 6 h, respec-
tively. Densitometry analysis of immunoblots was carried out 
using a Scion Image software. The relative levels of phospho-
STAT3 were expressed as the ratio to β-actin. The values 
shown are Mean ± SD for four separate experiments. Cells 
from each one of the four dermal fibroblast donors were 
used for one independent experiment. † P < 0.05 compared 
with the response to medium alone (Con); * P < 0.05 com-
pared with the response to thrombin alone.BMC Cell Biology 2007, 8:14 http://www.biomedcentral.com/1471-2121/8/14
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It seems likely that thrombin induced proMMP-9 release
was associated with JAK/STAT3, but not MAPK/ERK and
PI3K/Akt signaling pathways as inhibitors of STAT3 was
able to inhibit thrombin induced proMMP-9 release. The
observations that thrombin was capable of stimulating
phosphorylation of STAT3, and that AG490 could inhibit
thrombin provoked phosphorylation of STAT3 indicate
further that thrombin induced proMMP-9 release is asso-
ciated with JAK/STAT3 signaling pathway in HDFs. How-
ever, AG490 itself inhibited basal phosphorylation of
STAT3, indicating phosphorylation of STAT3 occurred
even when these cells were not under stimulation. Pro-
voking phosphorylation of STAT3 by thrombin has been
found with vascular smooth muscle cells previously [19].
Although PD98059, a specific inhibitor of MAPK pathway
eliminated thrombin induced phosphorylation of ERK1/
2, it failed to significantly inhibit thrombin induced
proMMP-9 release from HDFs, indicating MAPK/ERK sig-
naling pathway is unlikely a major pathway for thrombin
induced proMMP-9 release. It may serve as a major sign-
aling pathway for thrombin induced other events in
HDFs, such as IL-8 release from HDFs[13] and prolifera-
tion of astrocytes [20].
Conclusion
Thrombin is a potent stimulus of proMMP-9 release from
HDFs. The action of thrombin on HDFs is most likely
through activation of PAR-1. JAK/STAT3 signaling path-
way is involved in proMMP-9 release from HDFs. Since
MMP-9 presents at elevated levels during early wound
healing [21] the finding in the present study may suggest
that thrombin is actively involved in tissue remodeling
process of new wound in skin.
Methods
Materials
Cell culture medium RPMI 1640 and fetal bovine serum
(FBS) were obtained from GIBCO BRL (Lifetechnologies,
Rockville, MD, USA). PD98059, AG490, LY294002, phos-
pho-p44/42 MAPK antibody, unphospho-p44/42 MAPK
antibody, phospho-Akt antibody, unphospho-Akt anti-
body, phospho-STAT3 antibody and unphospho-STAT3
antibody were purchased from Cell Signaling Technology
(Beverly, MA, USA). Human thrombin (T6884), biotin
conjugated goat anti-rabbit immunoglobulins, biotin
conjugated goat anti-mouse immunoglobulins, extr-Avi-
din-peroxidase, mouse anti-human β-actin and antibiot-
ics (a mixture of penicillin and streptomycin) were from
Sigma (St. Louis, MO, USA). Recombinant hirudin (cata-
log number 377950) was from Calbiochem (San Diego,
CA, USA). PAR-1 agonist peptide (SFLLR-NH2) and its
reverse peptide (RLLFS-NH2) were synthesized at the Xian
Meiliang Co. (Xian, China). Mouse anti-human PAR-1,
mouse anti-human PAR-2, anti-PAR-3 rabbit polyclonal
antibody, anti-PAR-4 rabbit polyclonal antibody, goat
anti-mouse IgG-cy3, goat anti-mouse IgG-FITC, goat anti-
rabbit IgG-FITC, mouse IgG, rabbit IgG and PAR-1 block-
ing antibody (ATAP2, against amino acids 42–55 of
thrombin receptor of human origin) were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Sybr green
was from Cambrex Bio Science (Baltimore, USA). Most of
the other reagents such as salt and buffer components
were analytical grade and obtained from Sigma (St. Louis,
MO, USA).
Cell culture
Samples of foreskins were obtained from four healthy
donors (aged 18, 18, 20, 21 years, respectively) undergo-
ing circumcision in the First Affiliated Hospital, Shantou
University Medical College. The study adhered to the ten-
Western blot analysis of effect of LY294002 (LY), a PI3K  pathway inhibitor on phosphorylation of Akt in HDFs Figure 8
Western blot analysis of effect of LY294002 (LY), a PI3K 
pathway inhibitor on phosphorylation of Akt in HDFs. Cells 
were incubated with LY (40 µM), thrombin (Th, 5 U/ml) or 
Th + LY at 37°C for 2 h or 6 h, respectively. Densitometry 
analysis of immunoblots was carried out using a Scion Image 
software. The relative levels of phospho-Akt were expressed 
as the ratio to β-actin. The values shown are Mean ± SD for 
four separate experiments. Cells from each one of the four 
dermal fibroblast donors were used for one independent 
experiment. † P < 0.05 compared with the response to 
medium alone (Con).BMC Cell Biology 2007, 8:14 http://www.biomedcentral.com/1471-2121/8/14
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ets of the Declaration of Helsinki, and all subjects signed
an informed consent form before undergoing circumci-
sion. HDFs were isolated by sequential enzymatic diges-
tions and cultured in RPMI 1640 medium supplemented
with 10% (vol/vol) FBS, 100 units/ml penicillin, and 100
µg/ml of streptomycin at 37°C in an atomosphere of 5%
CO2 until confluent islands of cells were observed. Since
cells displayed the typical properties of spindle-shaped
fibroblasts after the third passage, only passages 3 to 6
HDFs were used for the study. The purity of HDFs was at
least 99% as assessed by detecting fibroblast marker using
immunostaining with a monoclonal mouse anti-human
fibroblast antibody (Dako, Glostrup, Denmark).
Detection of PARs in HDFs by immunofluorescence 
staining
Confluent fibroblasts were treated with nonenzymatic cell
dissociation fluid to obtain single-cell suspensions. After
being seeded onto eight-well chamber slides (Lab-Tek Per-
manox, Nunc, Life Technologies) at a density of 1 × 104
cells/well in 300 µl of RPMI 1640 containing 10% FBS,
HDFs were incubated in a humidified atmosphere of air
containing 5% CO2 for 48 h at 37°C, and then fixed with
4% paraformaldehyde for 3 min at room temperature.
The fixed cells were incubated with mouse anti-human
PAR-1, mouse anti-human PAR-2, rabbit anti-human
PAR-3, or rabbit anti-human PAR-4 antibody, respectively
for 16 h at 4°C. This was followed by addition of the sec-
ondary antibodies including goat anti-mouse IgG-cy3 (for
PAR-1), goat anti-mouse-FITC (for PAR-2) or goat anti-
rabbit IgG-FITC (for PAR-3 and PAR-4) for 60 mins at
room temperature. Mouse IgG or rabbit serum (20 ng/ml)
was used as negative controls. After three washes with
PBS, the chambers were removed, and coverslips were
mounted with an antifade glycerol-PBS-based mountant
(Dako, Glostrup, Denmark). The cells were visualized by
using a confocal microscope (D-ECLIPSE C1, Nikon).
Challenge of HDFs with thrombin and SFLLR-NH2
The cells were plated in 24-well tissue culture plates (5 ×
104/well) and serum starved with serum-free medium
overnight. After washing, the fresh medium with various
concentrations of thrombin (0.1, 1, 5 U/ml, U = NIH unit,
1 U/ml = 6.7 nM), SFLLR-NH2 (1, 10, 100 µM), hirudin
(1, 5 U/ml) or thrombin with hirudin was added into
each well for 6 h. TGFβ at 10 ng/ml was used as a positive
control. The culture supernatant was then collected and
stored at -80°C for subsequent analysis.
RT-PCR analysis of expression of PARs and MMP-9 genes 
in HDFs
After being exposed to various stimuli for 6 h, the total
RNA of HDFs was extracted by using an RNeasy Mini Kit
(Qiagen, Germany). cDNA was synthesized from 2 µg of
RNA by using ProtoScript First Strand cDNA Synthesis Kit
(Biolabs, New England, USA) according to the manufac-
turer's instructions. The cDNA was amplified using for-
ward and reverse specific primers for amplifying human
PARs.  β-actin was used as an internal control. Primers
were designed based on PAR sequences in Genbank using
Omiga software and prepared by BioAsia Co.. The primer
sequences were summarized in Table 1. Cycling condi-
tions were as follows: PAR-1, PAR-2, PAR-3, PAR-4, 30
cycles at 94°C for 1 min, 60°C for 1 min, and 72°C for
1.5 min; β-actin was amplified for 30 cycles at 94°C for 1
min, 55°C for 1 min and 72°C for 1 min. The reaction for
MMP-9 was allowed to proceed for 30 cycles at 94°C for
30 s, 57°C for 45 s, and 72°C for 45 s. The quality of the
PCR product was analyzed on a 1.5% agarose gel, visual-
ized with Sybr green and photographed under UV light.
The results were expressed as the ratio of mRNAs of PARs
or MMP-9 to β-actin after determination of the density of
the bands on agarose gel by densitometer.
Detection of proMMP-2 and proMMP-9 activities by 
gelatin zymography
Metalloproteinases generated in culture supernatants
were determined using gelatin zymography. Commercial
available gelatinases A and B (2 µg; USbiological, New
Orleans, LA, USA) were used as standards. Samples or
standards were added to platelet-monocyte conditioned
medium. The mixture was then placed in 2 × non-reduc-
Table 1: Primer sequences for PARs and MMP-9
Primer Sequence Size of product (bp)
PAR-1 sense 5'-CAGCTCCTGGCTGACACTCTTTGTC-3' 500
antisense 5'-CGAGCAGGGTTTCATTGAGCACAT-3'
PAR-2 sense 5'-GTGGATGAGTTTCTGCATCTGTCCTCA-3' 328
antisense 5'-CTGAGGCAGGTCATGGTCATGAAGAGAATGC-3'
PAR-3 sense 5'-GGCTGGACAGGAGCCACGAT-3' 403
antisense 5'-AGCGGTTGATGCTGATGCAGG-3'
PAR-4 sense 5'-GGATCGCCTACCACCTGCGTG-3' 401
antisense 5'-CCCGTAGCACAGCAGCATGG-3'
β-actin sense 5'-AGGGGCCGGACTCGTCATACT-3' 202
antisense 5'-GGCGGCAACACCATGTACCCT-3'
MMP-9 sense 5'-CGCCGCTCACCTTCAC-3' 185
antisense 5'-GCCCAGGGACCACAACT-3'BMC Cell Biology 2007, 8:14 http://www.biomedcentral.com/1471-2121/8/14
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ing SDS sample buffer and electrophoresed in a 10% poly-
acrylamide gel containing 0.1% gelatin. Following rinsing
in 2.5% Triton X-100 for 1 h and in distilled H2O for 2 h
at room temperature the gel was subsequently incubated
at 37°C for 24 h in the substrate buffer containing 50
mmol/L Tris-base (pH 7.6) and 5 mmol/L CaCl2. After
staining with Coomassie Blue and destaining, the pres-
ence of gelatinases in the gel was identified as clear bands
on a uniform blue and was quantified by densitometry.
The density units were integrated optic density, which was
area timed optical density. The ScionImage program was
used to quantify the band. Identification of each type of
gelatinase on the gel is based on the bands produced by
the gelatinase standards.
Western blot analysis of signal transduction pathways in 
HDFs upon thrombin stimulation
To determine the optimal concentrations of the inhibitors
of signal transduction pathways in HDFs, 25 and 50 µM
of PD98059, 20 and 40 µM of LY294002, and 20 and 40
µM of AG490 were preincubated with HDFs for 30 min-
utes prior to adding 5 U/ml thrombin. Since 50 µM of
PD98059, 40 µM of LY294002 and 40 µM of AG490
almost completely abolished thrombin-induced phos-
phorylation of ERK1/2, Akt and STAT3 respectively (data
not shown), whereas 25 µM of PD98059, 20 M of
LY294002 and 20 µM of AG490 inhibited thrombin-
induced phosphorylation of ERK1/2, Akt and STAT3 by
approximately only 30%, 27% and 40% respectively, the
higher concentration of each inhibitor was chosen as the
optimal concentration throughout the study.
HDFs, which were planted in 12-well tissue culture plates,
1 × 106 per well, were serum starved overnight and then
treated with 50 µM of PD98059, 40 µM of LY294002 or
40 µM of AG490 for 30 min prior to addition of 5 U/ml
thrombin. We examined the levels of downstream prod-
ucts of the following pathways: phospho-ERK1/2 in
MAPK/ERK pathway, phospho-Akt in the PI3K/Akt path-
way, and phospho-STAT3 in the JAK/STAT3 pathway. The
levels of these products were determined at 30 min (for
phospho-STAT3 only), 2 h and 6 h time points. The levels
of proMMP-2 and proMMP-9 in the supernatants were
determined by zymography.
The cells were lysed in phosphorylation lysis buffer
(0.5%Triton X-100, 150 mM NaCl, 200 µM sodium
orthovanadate, 10 mM sodium pyrophosphate, 100 mM
sodium fluoride, 1 mM EDTA, 50 mM Hepes, 1.5 mM
magnesium chloride, 10% glycerol, 1 mM phenylmethyl-
sulfonyl fluoride, and 10 µg/ml aprotinin) for 60 min at
4°C. After removing cell debris by centrifugation at
10,000 g for 30 min, the supernatants were collected.
Equal amount of the cell extracts were loaded on 10%
polyacrylamide gel for electrophoresis. Proteins in the gel
were then transferred onto polyvinylidene difluoride
(PVDF) membranes (Millipore Corporation, Billerica,
MA). Following blocking the membranes with 5% skim
milk in TBST (50 mM Tris, 0.15 M NaCl, 0.1% Tween 20,
pH 7.6) for 1 h at room temperature, the primary anti-
body was added. Biotinylated goat anti-rabbit immu-
noglobulins or biotinylated goat anti-mouse
immunoglobulins were used as secondary antibodies,
which was followed by addition of extr-Avidin-peroxi-
dase. The protein bands were detected by a chemilumines-
cence method according to manufacturer's instructions
(supersignal West Pico, Pierce). Radiographs were photo-
graphed with a digital scanning system. The same mem-
branes were stripped at 55°C for 30 min in stripped buffer
containing 0.7% β-mercaptoethanol, 2% SDS, and 62.5
mM Tris (pH 6.8) prior to being stained with mouse anti-
human β-actin monoclonal antibody as described above.
Densitometry analysis of immunoblots was carried out
using ScionImage software. The relative levels of phos-
pho-ERK1/2, Akt, and STAT3 were expressed as the ratio
to β-actin.
Statistical analysis
All data were expressed as mean ± SD. Each experiment
was repeated four times. Statistical analysis was per-
formed using one-way ANOVA or Students's t test with
SPSS (version12.0). P value less than 0.05 was considered
as statistically significant.
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